Table 3.
Characteristics and clinical data of patients
| TP group | NTP group | ||
| n = 17 | n = 20 | P-value | |
| Age (years) | 53.5±23.9 | 58.5±23.5 | 0.549a |
| Height (cm) | 151.8±20.6 | 150.8±24.7 | 0.905a |
| Body weight (kg) | 55.1±20.8 | 53.4±24.5 | 0.818a |
| Duration of LZD treatment (day), median (range) | 16.0 (15–30) | 17.5 (15–164) | 0.124a |
| Daily-per kg-dose (mg/kg/day) | 22.1±5.3 | 22.2±6.0 | 0.961a |
| Serum Creatinine (mg/dL) | 1.14±1.83 | 0.99±0.94 | 0.774a |
| CCr (mL/min) | 86.3±38.6 | 92.5±56.7 | 0.708a |
| Baseline platelet (×103/μL) | 235.35±87.3 | 232.8±71.3 | 0.924a |
| CRP (mg/dL) | |||
| before administration | 4.69±7.21 | 8.42±6.83 | 0.132a |
| 14 days post-administration | 2.23±3.54 | 1.15±1.29 | 0.278a |
| Decrease rate of CRP at Day14 (%) | 42±47 | 76±32 | 0.034a |
| Small decrease rate of CRP, n (%) | 13 (76) | 6 (30) | 0.008b |
| Route of LZD administration | 0.244b | ||
| Intravenous, n (%) | 1 (6) | 5 (25) | |
| Intravenous + Oral, n (%) | 5 (29) | 7 (35) | |
| Oral, n (%) | 11 (65) | 8 (40) | |
| Surgery, n (%) | 11 (65) | 14 (70) | 1.000b |
| Baseline disease | |||
| Chronic inflammatory disease, n (%) | 2 (12) | 5 (25) | 0.416b |
| Diabetes mellitus, n (%) | 4 (24) | 7 (35) | 0.495b |
| Chronic kidney disease, n (%) | 3 (18) | 5 (25) | 0.701b |
| Hypertension, n (%) | 6 (35) | 6 (30) | 1.000b |
| Hematological disease, n (%) | 0 (0) | 2 (10) | 0.489b |
| Vascular disease, n (%) | 9 (53) | 15 (75) | 0.188b |
| Respiratory disease, n (%) | 5 (29) | 10 (50) | 0.315b |
| Neoplasm, n (%) | 4 (24) | 9 (45) | 0.173b |
aWelch’s t-test, bFisher’s exact test